Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) was upgraded by stock analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Monday.

EGRX has been the topic of several other reports. BidaskClub lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 30th. Zacks Investment Research upgraded Eagle Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 10th. Royal Bank Of Canada set a $94.00 price objective on Eagle Pharmaceuticals and gave the company a “buy” rating in a research note on Sunday, July 16th. Mizuho cut their price objective on Eagle Pharmaceuticals from $40.00 to $37.00 and set an “underperform” rating on the stock in a report on Wednesday, September 6th. Finally, Piper Jaffray Companies set a $118.00 target price on Eagle Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, July 25th. Three investment analysts have rated the stock with a sell rating and four have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $74.80.

Eagle Pharmaceuticals (NASDAQ EGRX) opened at 60.49 on Monday. The stock’s 50 day moving average is $57.16 and its 200-day moving average is $71.75. The stock has a market capitalization of $917.57 million, a price-to-earnings ratio of 10.16 and a beta of 1.31. Eagle Pharmaceuticals has a 12 month low of $45.05 and a 12 month high of $97.15.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported $0.33 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.51 by ($0.18). Eagle Pharmaceuticals had a net margin of 39.32% and a return on equity of 66.30%. The company had revenue of $50.10 million during the quarter, compared to analysts’ expectations of $52.52 million. During the same quarter last year, the firm posted $0.80 earnings per share. The firm’s quarterly revenue was up 22.5% on a year-over-year basis. On average, equities research analysts expect that Eagle Pharmaceuticals will post $3.70 earnings per share for the current year.

Eagle Pharmaceuticals declared that its board has approved a stock repurchase plan on Wednesday, August 9th that allows the company to repurchase $100.00 million in outstanding shares. This repurchase authorization allows the specialty pharmaceutical company to buy up to 13.3% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: “Eagle Pharmaceuticals, Inc. (EGRX) Stock Rating Upgraded by ValuEngine” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/eagle-pharmaceuticals-inc-egrx-stock-rating-upgraded-by-valuengine.html.

In other Eagle Pharmaceuticals news, Director Douglas L. Braunstein acquired 20,400 shares of the stock in a transaction dated Wednesday, August 9th. The stock was acquired at an average cost of $49.07 per share, with a total value of $1,001,028.00. The transaction was disclosed in a filing with the SEC, which is accessible through this link. 19.50% of the stock is owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Kopp Investment Advisors LLC raised its holdings in Eagle Pharmaceuticals by 0.3% during the second quarter. Kopp Investment Advisors LLC now owns 3,060 shares of the specialty pharmaceutical company’s stock worth $241,000 after purchasing an additional 10 shares in the last quarter. Alps Advisors Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.3% during the 2nd quarter. Alps Advisors Inc. now owns 5,985 shares of the specialty pharmaceutical company’s stock worth $472,000 after buying an additional 16 shares during the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Eagle Pharmaceuticals by 0.7% during the 2nd quarter. PNC Financial Services Group Inc. now owns 11,269 shares of the specialty pharmaceutical company’s stock worth $889,000 after buying an additional 82 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Eagle Pharmaceuticals by 2.4% during the 1st quarter. Arizona State Retirement System now owns 4,200 shares of the specialty pharmaceutical company’s stock worth $348,000 after buying an additional 100 shares during the last quarter. Finally, D.A. Davidson & CO. boosted its holdings in shares of Eagle Pharmaceuticals by 2.4% in the 2nd quarter. D.A. Davidson & CO. now owns 4,350 shares of the specialty pharmaceutical company’s stock valued at $343,000 after buying an additional 100 shares in the last quarter.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Receive News & Stock Ratings for Eagle Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.